Takeda Commences Final Trial For Once-Weekly DPP-4 Inhibitor
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical Sept. 8 announced the start of a final Phase III trial for SYR-472, a once-weekly DPP-4 inhibitor for type 2 diabetes